The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 7, 2008, Pages 1272-1281

  Willhauck, Michael J ^a   Samani, Bibi Rana Sharif ^a   Wolf, Ingo ^b   Senekowitsch Schmidtke, Reingard ^b   Stark, Hans Jürgen ^c   Meyer, Geerd J ^d   Knapp, Wolfram H ^d   Göke, Burkhard ^a   Morris, John C ^e   Spitzweg, Christine ^a,f  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MAYO CLINIC   (United States)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

211At therapy; Gene therapy; Prostate cancer; PSA promoter; Sodium iodide symporter

Indexed keywords

ASTATINE 211; PROSTATE SPECIFIC ANTIGEN; SODIUM IODIDE SYMPORTER; ASTATINE; COTRANSPORTER; RECOMBINANT PROTEIN;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CELL SPECIFICITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; TRANSPORT KINETICS; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ASTATINE; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SYMPORTERS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 45049086826     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0775-4     Document Type: Article

References (46)

1. Stearns ME, McGarvey T. Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest. 1992;67(5):540-52.
2. Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. J Urol. 2001;166:1220-33.
3. Mazzaferri EL. Carcinoma of follicular epithelium: Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD, editors. The thyroid: a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven; 1996. p. 922-45.
4. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458-60.
5. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001;86(7):3327-35.
6. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526-30.
7. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver BD, Heufelder AE, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59:2136-41.
8. Spitzweg C, Scholz IV, Bergert ER, Tindall DJ, Young CY, Göke B, et al. Retinoic acid-induced stimulation of sodium iodide symporter (NIS) expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology. 2003;144:3423-32.
9. Scholz IV, Cengic N, Goke B, Morris JC, Spitzweg C. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab. 2004;89(3):1108-16.
10. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001;8(20):1524-31.
11. Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL, et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther. 2005;12(5):835-41.
12. Haberkorn U, Kinscherf R, Kissel M, Kübler W, Mahmut M, Sieger S, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther. 2003;10:774-80.
13. Carlin S, Cunningham SH, Boyd M, McCluskey AG, Mairs RJ. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Therapy. 2000;7:1529-36.
14. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol. 2002;57:559-74.
15. Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2002;29(7):842-54.
16. Carlin S, Akabani G, Zalutsky MR. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med. 2003;44(11):1827-38.
17. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocrine Rev. 2003;24(1):48-77.
18. Van Sande J, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE, et al. Anion selectivity by the sodium iodide symporter. Endocrinology. 2003;144(1):247-52.
19. Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med. 2005;46(Suppl 1):151S-6S.
20. Helmekea HJ, Mahnke E, Schaardt U, Knapp WH. External targets for the production of 211At-review and status of the target development at the Hannover cyclotron. Z Med Phys. 2004;14(3):195-9.
21. Weiss SJ, Philp NJ, Grollman EF. Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984;114:1090-8.
22. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59(3):661-8.
23. 188Re as an alternative radionuclide for treatment of prostate cancer following tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab. 2007;92:4451-8.
24. Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab. 2005;90(8):4457-64.
25. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res. 2005;11:1483-9.
26. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther. 2006;17(6):661-8.
27. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther. 2006;13(1):60-6.
28. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 2003;63(22):7840-4.
29. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther. 2005;12(3):272-80.
30. Spitzweg C, Baker C, Bergert ER, O'Connor MK, Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer following carcinoembryonic antigen (CEA)-promoter-targeted sodium iodide symporter (NIS) gene expression. Hum Gene Ther. 2007;18(10):916-24.
31. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood. 2003;102:489-96.
32. Sieger S, Jiang S, Schönsiegel F, Eskerski H, Kübler W, Altmann A, et al. Tumor-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med Mol Imaging. 2003;30(5):748-56.
33. Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med. 2001;42:317-25.
34. Smit JW, Schroder-Van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D, et al. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab. 2002;87(3):1247-53.
35. Shimura H, Haraguchi K, Myazaki A, Endo T, Onaya T. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology. 1997;138(10):4493-6.
36. Petrich T, Quintanilla-Martinez L, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ, et al. Effective cancer therapy with the a-particle emitter [211-At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res. 2006;12(4):1342-8.
37. Carlin S, Mairs RJ, Welsh P, Zalutsky MR. Sodium-iodide symporter (NIS)-mediated accumulation of (211At)astatide in NIS-transfected human cancer cells. Nucl Med Biol. 2002;29:729-39.
38. Lindencrona U, Nilsson M, Forssell-Aronsson E. Similarities and differences between free 211At and 125I-transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nucl Med Biol. 2001;28(1):41-50.
39. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother (Berl). 1988;29(6):631-58.
40. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871-8.
41. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab. 1999;84(11):4178-84.
42. Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, et al. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004;10:4294-302.
43. McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys. 1996;35(1):69-80.
44. Behr M, Schmitt TL, Espinoza CR, Loos U. Cloning of a functional promoter of the human sodium/iodide symporter gene. Biochem J. 1998;331:359-63.
45. Back T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med. 2005;46(12):2061-7.
46. Russ V, Elfberg H, Thoma C, Kloeckner J, Ogris M, Wagner E. Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. Gene Ther. 2008;15(1):18-29.